Granules India Limited (GRANULES) — Announcement | 3 June 2026

StockFin.ai

Try Free

Granules India announced its US subsidiary Granules Pharmaceuticals received a USFDA Establishment Inspection Report with Voluntary Action Indicated classification for its Chantilly facility, confirming regulatory compliance after a March-April 2026 inspection with four Form 483 observations. The company reaffirmed its commitment to quality standards across global manufacturing sites while maintaining operations in India, the US, and Switzerland with regulatory approvals from major authorities.

📄 View Original Announcement (PDF)

📊 Stock Analysis — GRANULES ✨ Ask AI About This

About Granules India Limited (GRANULES)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹18,242.81 Cr P/E: 37.2

View full GRANULES stock details →

📡 Get AI alerts when GRANULES files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track GRANULES — Free

💡 Ask AI about this filing

"How does this announcement affect Granules India Limited's outlook?" "What did Granules India Limited announce on 3 June 2026?" "Is this positive or negative for GRANULES?"

Ask AI Free →

📊 More GRANULES filings

See all GRANULES filings →

🔥 Also filed on 3 June 2026

PRAJIND Praj Industries Limited Financial Results PRECOT Precot Limited Announcement PREMEXPLN Premier Explosives Limited Announcement PREMIERENE Premier Energies Limited Announcement PTCIL PTC Industries Limited Financial Results PRAJIND Praj Industries Limited Announcement

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when GRANULES files new disclosures

Track GRANULES filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track GRANULES — Free

Free account · 2 AI queries/day